An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB)

A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation

Bonnie W. Ramsey, Jane C. Davies, Noel G. McElvaney et al. · New England Journal of Medicine · 2011 · 2.1K citations · Full text

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Fredrick Van Goor, Sabine Hadidaꝉ, Peter D. J. Grootenhuis et al. · Proceedings of the National Academy of Sciences · 2009 · 1.2K citations · Full text

Inflammation, Fibrosis, Molecular Physiology +15

Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report

Philip M. Farrell, Beryl J. Rosenstein, Terry B. White et al. · The Journal of Pediatrics · 2008 · 1.1K citations · Full text

Early Diagnosis, Neonatology, Pediatrics +4

Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation

Philip M. Farrell, Terry B. White, Clement L. Ren et al. · The Journal of Pediatrics · 2017 · 897 citations · Full text

Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a <i>G551D</i> Mutation

Jane C. Davies, Claire Wainwright, Gerard J. Canny et al. · American Journal of Respiratory and Critical Care Medicine · 2013 · 499 citations · Full text